Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PastoCys
- Development stage
- Unknown
- Lead developer
- Pasteur Institute of Iran
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravesical
01
Overview
PastoCys is a live-attenuated preparation of the **Bacillus Calmette-Guérin (BCG) Pasteur strain**, specifically formulated for intravesical immunotherapy. It is primarily indicated for the treatment of non-muscle-invasive bladder cancer (NMIBC), including carcinoma in situ (CIS) and as an adjuvant treatment following transurethral resection of bladder tumors (TURBT) to prevent recurrence and progression. Developed by the Pasteur Institute of Iran, PastoCys works by inducing a potent local inflammatory and cellular immune response within the bladder wall. Upon instillation, the mycobacteria adhere to the urothelium and are internalized by bladder cells, triggering the release of Th1 cytokines and the recruitment of cytotoxic T lymphocytes, macrophages, and natural killer cells that target and eliminate malignant cells.
- Brand names
- PastoCys
- Other names
- BCG PasteurBacillus Calmette-Guérin Pasteur strainIntravesical BCG
02
Targets
TLR4 (Toll-like receptor 4)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on PastoCys.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PastoCys.